Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H17ClF3NO4 |
Molecular Weight | 415.791 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NCCOC(=O)C(OC1=CC=CC(=C1)C(F)(F)F)C2=CC=C(Cl)C=C2
InChI
InChIKey=BJBCSGQLZQGGIQ-UHFFFAOYSA-N
InChI=1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)
Molecular Formula | C19H17ClF3NO4 |
Molecular Weight | 415.791 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Halofenate (MK-185) was invented as a hypolipidemic and hypouricemic agent. It was shown that halofenate lower serum triglycerides and uric acid in patients with a variety of hyperlipidemias. Treatment of dyslipidemic type 2 diabetic patients also showed triglyceride lowering and, surprisingly, significant reductions in plasma glucose and insulin. Halofenate is a selective PPAR-γ modulator (SPPARγM). SPPARγMs are believed to bind in distinct manners to the ligand-binding pocket of PPAR-γ, leading to altered receptor conformational stability and resulting in distinct patterns of gene expression. Thus, was suggested that halofenate hold promising therapeutic potential in the treatment of type 2 diabetes, without the side effects. However, information about the current use of this compound is not available.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate). | 1971 May-Jun |
|
Effect of halofenate and clofibrate on lipid synthesis in rat adipocytes. | 1975 Feb 20 |
|
Halofenate. Its selection and trial as a primary uricosuric agent. | 1975 Nov-Dec |
|
The effect of halofenate or halofenate free acid on human, rat and guinea pig platelet aggregation. | 1976 Apr 30 |
|
Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator. | 2010 Apr 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6368149
Combined halofenate-chlorpropamide was evaluated for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). Four subjects treated with 500 mg/day chlorpropamide were given 500-1000 mg halofenate daily for 48 wk or longer.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:17:29 GMT 2023
by
admin
on
Fri Dec 15 15:17:29 GMT 2023
|
Record UNII |
K9TZK4MNO6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C921
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
||
|
NCI_THESAURUS |
C29703
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2536
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
PRIMARY | |||
|
K9TZK4MNO6
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
PRIMARY | |||
|
24091-96-1
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
SUPERSEDED | |||
|
SUB07999MIG
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL456071
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
PRIMARY | |||
|
C83805
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
PRIMARY | |||
|
33584
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
PRIMARY | |||
|
D006218
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
PRIMARY | |||
|
DTXSID9023120
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
PRIMARY | |||
|
100000083922
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
PRIMARY | |||
|
26718-25-2
Created by
admin on Fri Dec 15 15:17:29 GMT 2023 , Edited by admin on Fri Dec 15 15:17:29 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE |
|